Emphasis on neoadjuvant therapy for “resectable” pancreatic cancer
The treatment concept for pancreatic cancer is being transferred from “surgery first” to MDT model. The postoperative adjuvant treatment of pancreatic cancer can significantly improve the prognosis of patients and has become the standardized diagnostic and treatment practice; the value and significa...
Main Author: | LIU Chang |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2015-05-01
|
Series: | Linchuang Gandanbing Zazhi |
Subjects: | |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=6483&ClassID=41585614 |
Similar Items
-
Current status and perspectives of neoadjuvant therapy for pancreatic cancer
by: LIANG Tingbo
Published: (2019-05-01) -
Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
by: Ren X, et al.
Published: (2019-01-01) -
Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
by: Fuyuhiko Motoi, et al.
Published: (2020-03-01) -
Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01) -
Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer
by: Liqiong Yang, et al.
Published: (2021-08-01)